Monitor IND filing for EB-003 as the primary catalyst. The S-3 shelf registration overhang limits near-term upside. Cash runway extension reduces near-term financing risk but further dilution is expected. No revenue or earnings catalyst imminent.
Price Chart
Executive Summary
Enveric Biosciences reported Q1 2026 results with a net loss of $1.6M ($1.08 per share) vs $2.2M in Q1 2025. Cash increased to $4.9M at quarter end, and subsequent capital raises (private placement and warrant exercises) boosted cash to ~$10.3M as of May 15, extending runway into Q1 2027. Pipeline progress on EB-003 continues but no revenue or near-term catalyst, while a recently filed S-3 shelf registration adds dilution risk.
Key Financial Metrics
Key Facts
- Net loss of $1.6M for Q1 2026, compared to $2.2M in Q1 2025
- Cash and cash equivalents of $4.9M at March 31, 2026
- Subsequent to Q1, raised $1.5M from warrant exercises and closed $13.9M private placement ($5M upfront)
- Cash balance of ~$10.3M as of May 15, 2026, expected to fund operations into Q1 2027
- Pipeline progress: IND-enabling studies for EB-003 ongoing; PGR petition withdrawal by AbbVie announced
- S-3 shelf registration filed on April 23, 2026, allows for future share sales
Financial Impact
Pre-revenue biotech; net loss improved to $1.6M from $2.2M YoY; cash runway extended to Q1 2027 via ~$6.5M net capital raised post-quarter
Risk Factors
- Dilution from S-3 shelf offering and warrant exercises
- Pre-revenue stage with no approved products
- Clinical development risk for EB-003 Phase 1 trial
- Potential need for additional capital beyond Q1 2027
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-023345 |
| Exhibit: ex99-1.htm | 0001493152-26-023345 |
| Document: 0001493152-26-023345-index-headers.html | 0001493152-26-023345 |
| Document: 0001493152-26-023345-index.html | 0001493152-26-023345 |
| Document: 0001493152-26-023345.txt | 0001493152-26-023345 |
| 8-K Data (Synthetic) | 0001493152-26-023345 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 10w ago | 8-K | $1.48 $1.46 | ▲ +1.35% | ▼ −0.63% | $1.38 (+6.76%) |
Jun 9, 2026 19w ago | 8-K | $1.62 $1.43 | ▲ +11.73% | ▲ +15.35% | $1.38 (+14.81%) |
Jun 9, 2026 19w ago | 424B5 | $1.62 $1.43 | ▲ +11.73% | ▲ +15.35% | $1.38 (+14.81%) |
May 29, 2026 21w ago | 8-K | $2.26 $1.38 | ▲ +38.94% | ▲ +37.64% | $1.38 (+38.94%) |
May 15, 2026 23w ago | 8-K | $2.25 $1.48 | ▼ −34.22% | ▼ −36.34% | $1.38 (−38.67%) |
Apr 23, 2026 26w ago | S-3 | $5.04 $2.22 | ▲ +55.95% | ▲ +59.98% | $1.38 (+72.62%) |
Apr 14, 2026 27w ago | DEFA14A | $2.03 $2.52 | ▲ +24.14% | ▲ +18.09% | $1.38 (−32.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers